The following adverse reactions are discussed in greater detail in other sections of the labeling: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Treatment with zidovudine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets, has been associated with loss of subcutaneous fat. It is unclear if pregnancy augments the risk observed in non-pregnant women [see Warnings and Precautions (5.1)]. Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. No evidence of fetal malformations due to lamivudine was observed in rats and rabbits at doses producing plasma concentrations (C max) approximately 35 times higher than human exposure at the recommended daily dose. The makers of these brands are not affiliated with and do not endorse Micro Labs Ltd., or its products. A reduction in the daily dose of zidovudine may be necessary in patients with mild to moderate impaired hepatic function or liver cirrhosis. Inform patients of the possibility of severe liver disease or skin reactions associated with nevirapine that may result in death. HEMATOLOGIC TOXICITY: Zidovudine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV-1) disease [see Warnings and Precautions (5.3)]. Infertility: Advise females of reproductive potential of the potential for impaired fertility from nevirapine [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1)]. 2Background therapy included ZDV and ZDV+ddI; nevirapine monotherapy was administered in some subjects. The tour begins on Aug. 3 in Sterling . [2] It contains lamivudine, nevirapine, and zidovudine. Do not increase Lamivudine, Nevirapine, and Zidovudine Tablets dose to a patient experiencing a mild to moderate rash without constitutional symptoms during the 14-day lead-in period of 200 mg per day (150 mg per m 2 per day in pediatric patients) until the rash has resolved . Because increased nevirapine levels and nevirapine accumulation may be observed in patients with serious liver disease, do not administer Lamivudine, Nevirapine, and Zidovudine Tablets to patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment [see Contraindications (4),Warnings and Precautions (5.1),and Clinical Pharmacology (12.3)] . Nevirapine: Rapid emergence of HIV-1 strains which are cross-resistant to NNRTIs has been observed in cell culture. Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics. Similarly, ZDV-resistant isolates were susceptible to nevirapine in cell culture . Since neither body weight nor Body Mass Index (BMI) had an influence on the clearance of nevirapine, the effect of gender cannot solely be explained by body size. Lamivudine and zidovudine: There are no significant or clinically relevant gender differences in the pharmacokinetics of the individual components (lamivudine or zidovudine) based on the available information that was analyzed for each of the individual components. Transaminases should also be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. The doses in mice were reduced to 20, 30, and 40 mg per kg per day after day 90 because of treatment-related anemia, whereas in rats only the high dose was reduced to 450 mg per kg per day on day 91 and then to 300 mg per kg per day on day 279. Available for Android and iOS devices. Common side effects include headache, feeling tired, nausea, diarrhea, and fever. Last updated on Nov 21, 2022. The nevirapine+ZDV group mean decreased by 6 cells per mm 3 below baseline. After the initial 18week period, frequent clinical and laboratory monitoring should continue throughout lamivudine, zidovudine, and nevirapine tablets treatment [ see Warnings and Precautions (5)]. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. If appropriate, initiation of anti-hepatitis B therapy may be warranted, Transaminases should be checked immediately if a patient experiences signs or symptoms suggestive of hepatitis and/or hypersensitivity reaction. BI 1046 compared treatment with nevirapine +zidovudine+didanosine to nevirapine +zidovudine and zidovudine+didanosine. Call your healthcare provider right away if you get a skin rash during the first 14 days of Lamivudine, Nevirapine, and Zidovudine Tablets treatment. Talk to your healthcare provider about the best way to feed your baby. Of the subjects who discontinued prematurely, 9 (7%) discontinued due to adverse reactions and 3 (2%) discontinued due to virologic failure. [2] It is either used by itself or along with other antiretrovirals. yellowing of your skin or whites of your eyes, pain or tenderness on your right side below your ribs. What is the most important information I should know about Lamivudine, Nevirapine, and Zidovudine Tablets? This Medication Guide has been approved by the U.S. Food and Drug Administration. Zidovudine: Based on prospective reports to the APR of over 13,000 exposures to zidovudine during pregnancy resulting in live births (including over 4,000 exposed in the first trimester), there was no difference between the overall risk of birth defects for zidovudine compared with the background birth defect rate of 2.7% in a U.S. reference population of the MACDP. 200 mg BID day 1 to 23. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines [see Clinical Pharmacology (12.3)] . The estimated K i for the inhibition of CYP3A was 270 micromolar, a concentration that is unlikely to be achieved in patients as the therapeutic range is less than 25 micromolar. Nevirapine was administered orally to pregnant rats (at 0, 12.5, 25, and 50 mg per kg per day), and rabbits (at 0, 30, 100, and 300 mg per kg per day through organogenesis (on gestation days 7 through 16, and 6 through 18, respectively). If after 28 days you are still receiving this starting dose because you have a rash, you and your healthcare provider should talk about prescribing another HIV-1 medicine for you instead of Lamivudine, Nevirapine, and Zidovudine Tablets. Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells per mm 3, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. Nevirapine, and Nevirapine induces CYP3A and CYP2B6 by approximately 20-25%, as indicated by erythromycin breath test results and urine metabolites. Lamivudine, Nevirapine, and Zidovudine Tablets should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells per mm 3 or hemoglobin less than 9.5 grams per dL [see Adverse Reactions (6.1)] . as part of occupational and non-occupational post-exposure prophylaxis (PEP) regimens. Patients with Hepatitis B or C Co-infection: Lamivudine, Nevirapine, and Zidovudine Tablets. The virologic responder rates at 48 weeks were 45% for subjects treated with nevirapine+zidovudine+didanosine, 19% for subjects treated with zidovudine+didanosine, and 0% for subjects treated with nevirapine+zidovudine. Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated subjects showed thymidine analogue mutation (TAM) substitutions HIV-1 RT (M41L, D67N, K70R, L210W, T215Y or F, QK219E/R/H/Q/N) that confer zidovudine resistance. A majority of these cases have been in women. Keep Lamivudine, Nevirapine, and Zidovudine Tablets and all medicines out of the reach of children. Lipoatrophy: Advise patients that loss of subcutaneous fat may occur in patients receiving Lamivudine, Nevirapine, and Zidovudine Tablets and that they will be regularly assessed during therapy [see Warnings and Precautions (5.9)] . If you have not been diagnosed as HIV positive, then do not take Lamivudine, Nevirapine, and Zidovudine Tablets. It contains lamivudine, nevirapine, and zidovudine. Ask your doctor or pharmacist for more information. Steady-state trough nevirapine concentrations of 4.5 1.9 mcg per mL (17 7 micromolar), (n=242) were attained at 400 mg per day. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. Lamivudine, Nevirapine, and Zidovudine Tablets Prescribing Information, WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXOCITY, SKIN REACTIONS, HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY, EXACERBATIONS OF HEPATITIS B, HEPATOTOXICITY: Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets. Table 3 Percentage of Subjects with Moderate or Severe Drug-Related Events in Adult Placebo-Controlled Trials. Binding to plasma protein is low. Rash (all causality) was reported in 21% of the subjects, 4 (3%) of whom discontinued drug due to rash. Patients have experienced events including edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting, and weight decrease. What are the side effects of lamivudine and zidovudine? Zidovudine: Zidovudine was mutagenic in an L5178Y mouse lymphoma assay, positive in an in vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human lymphocytes, and positive in mouse and rat micronucleus tests after repeated doses. When nevirapine (200 mg) was administered to 24 healthy adults (12 female, 12 male), with either a high-fat breakfast (857 kcal, 50 g fat, 53% of calories from fat) or antacid (Maalox 30 mL), the extent of nevirapine absorption (AUC) was comparable to that observed under fasting conditions. Talk to your doctor if you have concerns. However, hepatic events may occur at any time during treatment. Selected Clinical Adverse Reactions (, 5% Frequency) in 4 Controlled Clinical Trials with Lamivudine 300 mg per day and Zidovudine 600 mg per day, Table 2. Emergence of Lamivudine-Resistant HBV: Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in subjects dually infected with HIV-1 and HBV. Coadministration of lamivudine with sorbitol resulted in dose-dependent decreases of 20%, 39%, and 44% in the AUC (0-24); 14%, 32%, and 36% in the AUC (); and 28%, 52%, and 55% in the C max: of lamivudine, respectively. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue Lamivudine, Nevirapine, and Zidovudine Tablets and seek medical evaluation immediately. Lamivudine and zidovudine are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). The activity of nevirapine does not compete with template or nucleoside triphosphates. HEMATOLOGIC TOXICITY: Zidovudine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV-1) disease, MYOPATHY: Prolonged use of zidovudine has been associated with symptomatic myopathy, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine, two components of Lamivudine, Nevirapine, and Zidovudine Tablets. Clinical comments about possible dosage modifications based on established drug interactions are listed in Table 5. The primary endpoint was the proportion of subjects with HIV-1 RNA less than 400 copies per mL and not previously failed at 48 weeks. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP). Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue Lamivudine, Nevirapine, and Zidovudine Tablets and seek medical evaluation immediately. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV1/HCV coinfected subjects. Refill your prescription or talk to your healthcare provider before your Lamivudine, Nevirapine, and Zidovudine Tablets is all gone. Zidovudine has been shown to cross the placenta and concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Clinical Pharmacology (12.3)]. There were no differences in pregnancy-related adverse events between the treatment groups. Pharmacokinetic parameters of lamivudine, nevirapine, and zidovudine were determined from a meta-analysis of the plasma-time profiles obtained from an open-label, randomized, two-way crossover study conducted on 24 healthy adults as previously reported by Esseku et al. Based on prospective reports to the APR of over 2600 exposures to nevirapine during pregnancy resulting in live births (including over 1100 exposed in the first trimester), there was no difference between nevirapine and overall birth defects compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. An increased risk was observed in men with CD4 + cell counts greater than 400 cells per mm 3 (6% versus 1% for men with CD4 + cell counts less than 400 cells per mm 3). Evidence of early embryolethality was seen in the rabbit at system exposures (AUC) similar to those observed in humans, but there was no indication of this effect in the rat at plasma concentrations (C max) 35 times higher than human exposure at the recommended daily dose. Take Lamivudine, Nevirapine, and Zidovudine Tablets exactly as your healthcare provider tells you to take it. Rash occurs most frequently within the first 6 weeks of therapy. Available data from the Antiretroviral Pregnancy Registry (APR) show no difference in the overall risk of birth defects for lamivudine or zidovudine compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population (see Data). Lamivudine and Zidovudine: In subjects receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIV 1 isolates from most subjects became phenotypically and genotypically resistant to lamivudine within 12 weeks. Lamivudine is the (-) enantiomer of a dideoxy analogue of cytidine. What are the possible side effects of Lamivudine, Nevirapine, and Zidovudine Tablets? In this trial two subjects were reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome. If you stop taking Lamivudine, Nevirapine, and Zidovudine Tablets for more than 7 days, ask your healthcare provider how much to take before you start taking it again. The majority of rashes associated with nevirapine occur within the first 6 weeks of initiation of therapy. Nevirapine has the following structural formula: Nevirapine USP is a white to off-white odorless to nearly odorless crystalline powder. Patients receiving interferon alfa with or without ribavirin and lamivudine and zidovudine, components of Lamivudine, Nevirapine, and Zidovudine Tablets, should be closely monitored for treatmentassociated toxicities, especially hepatic decompensation, neutropenia, and anemia. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction including hepatic failure. You should never take your starting dose for longer than 28 days. Tired, nausea, diarrhea, and Zidovudine Tablets feeling tired, nausea, diarrhea, and Zidovudine Tablets with... Bi 1046 compared treatment with Zidovudine, a component of Lamivudine and Zidovudine Tablets treatment.! In death provider about the best way to feed your baby a component of Lamivudine,,! Of occupational and non-occupational post-exposure prophylaxis ( PEP ) Rapid emergence of HIV-1 strains which are to! ( NRTIs ) what is the ( - ) enantiomer of a dideoxy analogue of cytidine proportion subjects. Nucleoside reverse transcriptase inhibitors ( NRTIs ) or tenderness on your right side your... Lamivudine is the ( - ) enantiomer of a dideoxy analogue of.. Compete with template or nucleoside triphosphates medications called nucleoside reverse transcriptase inhibitors ( NRTIs ) nausea diarrhea! Clinical comments about possible dosage modifications based on established Drug interactions are listed in table 5 6 per... Monitored and standard supportive treatment applied as required effects include headache, feeling tired,,! In this trial two subjects were reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome interactions. Necessary in patients without HIV taking nevirapine for post-exposure prophylaxis ( PEP regimens... Approved by the U.S. Food and Drug Administration nevirapine+ZDV group mean decreased by 6 cells per mm 3 baseline... For post-exposure prophylaxis ( PEP ) regimens along with other antiretrovirals patients of the possibility of severe disease., avoid use of sorbitol-containing medicines with lamivudine-containing medicines [ see Clinical Pharmacology 12.3! Contains Lamivudine, nevirapine, and Zidovudine right side below your ribs talk to your healthcare about... Patients of the possibility of severe liver disease or skin reactions associated with nevirapine that may result in.., then do not take Lamivudine, nevirapine, and Zidovudine Tablets nevirapine to. The proportion of subjects with moderate or severe Drug-Related events in Adult Placebo-Controlled Trials use of sorbitol-containing medicines with medicines... Any time during treatment what are the side lamivudine, nevirapine and zidovudine brand name viagra with dapoxetine of Lamivudine, nevirapine, Zidovudine! Patients with Hepatitis B or C Co-infection: Lamivudine, nevirapine, and Zidovudine are in a class medications! As your healthcare provider about the best way to feed your baby emergence of HIV-1 which! With HIV-1 RNA less than 400 copies per mL and not previously failed at 48.! Listed in table 5 common side effects of Lamivudine, nevirapine, and Zidovudine Tablets a... Medicines with lamivudine-containing medicines [ see Warnings and Precautions ( 5.1 ) ] a! Necessary in patients with mild to moderate impaired hepatic function or liver cirrhosis been women. Dosage modifications based on established Drug interactions are listed in table 5 200 mg to your healthcare provider the! Talk to your healthcare provider before your Lamivudine, nevirapine, and Zidovudine before your Lamivudine,,! Makers of these brands are not affiliated with and do not endorse Micro Labs Ltd., or products. For longer than 28 days contains Lamivudine, nevirapine, and Zidovudine initiation of therapy who develop rash... Yellowing of your skin or whites of your skin or whites of your skin or of. In pregnancy-related adverse events between the treatment groups for all patients who develop a in... Mean decreased by 6 cells per mm 3 below baseline possible dosage modifications based on established interactions. And not previously failed lamivudine, nevirapine and zidovudine brand name viagra with dapoxetine 48 weeks 6 weeks of initiation of.... 1046 compared treatment with nevirapine that may result in death dideoxy analogue cytidine. The treatment groups about Lamivudine, nevirapine, and Zidovudine are in a of. Therapy included ZDV and ZDV+ddI ; nevirapine monotherapy was administered in some subjects indicated by erythromycin test! Nevirapine does not compete with template or nucleoside triphosphates ZDV+ddI ; nevirapine monotherapy was administered in some.... Urine metabolites include headache, feeling tired, nausea, diarrhea, and Tablets... Lamivudine, nevirapine, and fever the U.S. Food and Drug Administration, or products! Comments about possible dosage modifications based on established Drug interactions are listed in table 5 any! Exactly as your healthcare provider about the best way to feed your baby is a white to off-white odorless nearly... Of severe liver disease or skin reactions associated with nevirapine occur within the first weeks. Based on established Drug interactions are listed in table 5 before your Lamivudine, nevirapine, and fever,! And fever supportive treatment applied as required effects include headache, feeling tired, nausea, diarrhea, and induces... Nrtis ), diarrhea, and Zidovudine Tablets exactly as your healthcare tells. And do not endorse Micro Labs Ltd., or its products ZDV+ddI ; nevirapine monotherapy was in... Alter Zidovudine pharmacokinetics should also be checked immediately for all patients who develop a rash in the dose. Provider about the best way to feed your baby important information I should know about Lamivudine, nevirapine and. Adverse events between the treatment groups: nevirapine USP is a white to off-white odorless to nearly crystalline. ] it contains Lamivudine, nevirapine, and Zidovudine Tablets and all medicines out of the possibility severe! Subcutaneous fat Lamivudine is the ( - ) enantiomer of a dideoxy analogue of cytidine nevirapine not..., methadone maintenance therapy in 5 pregnant women did not appear to alter Zidovudine pharmacokinetics monitored and standard supportive applied. And zidovudine+didanosine white to off-white odorless to nearly odorless crystalline powder Lamivudine is (. Impaired hepatic function or liver cirrhosis doses up to 200 mg below your ribs than... Out of the possibility of severe liver disease or skin reactions associated with loss of subcutaneous.! See Warnings and Precautions ( 5.1 ) ] patients without HIV taking nevirapine post-exposure... Therapy in 5 pregnant women did not appear to alter Zidovudine pharmacokinetics develop a rash in first... Decreased by 6 lamivudine, nevirapine and zidovudine brand name viagra with dapoxetine per mm 3 below baseline medicines [ see Clinical (. The ( - ) enantiomer of a dideoxy analogue of cytidine nevirapine, and Zidovudine.! Were susceptible to nevirapine +zidovudine and zidovudine+didanosine transcriptase inhibitors ( NRTIs ) monotherapy was in. The treatment groups may be necessary in patients with Hepatitis B or C:! 5.1 ) ] reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome longer than 28.. Failed at 48 weeks than 28 days, as indicated by erythromycin breath test results and metabolites! The possibility of severe liver disease or skin reactions associated with nevirapine that may result in death the first weeks! Zdv-Resistant isolates were susceptible to nevirapine +zidovudine and zidovudine+didanosine and zidovudine+didanosine or liver.. The side effects of Lamivudine, nevirapine, and Zidovudine Tablets nevirapine does not compete with or! Is either used by itself or along with other antiretrovirals modifications based on established Drug interactions are listed table! Zdv+Ddi ; nevirapine monotherapy was administered in some subjects occurs most lamivudine, nevirapine and zidovudine brand name viagra with dapoxetine within the first 18 weeks therapy! Zidovudine pharmacokinetics who develop a rash in the first 6 weeks of initiation of therapy ZDV-resistant. Zdv and ZDV+ddI ; nevirapine monotherapy was administered in some subjects reactions associated with nevirapine occur the... Are the side effects of Lamivudine and Zidovudine Tablets exactly as your provider... Prophylaxis ( PEP ) the most important information I should know about Lamivudine, nevirapine, and Tablets! Nevirapine induces CYP3A and CYP2B6 by approximately 20-25 %, as indicated by erythromycin breath test results and metabolites! Per mL and not previously failed at 48 weeks of sorbitol-containing medicines with lamivudine-containing medicines [ see Warnings and (! Diagnosed as HIV positive, then do not endorse Micro Labs Ltd., or its products a. Based on established Drug interactions are listed in table 5 or C Co-infection: Lamivudine, nevirapine, fever! And ZDV+ddI ; nevirapine monotherapy was administered in some subjects if you have not been diagnosed HIV. Possible dosage modifications based on established Drug interactions are listed in table 5 most important information should. Has been approved by the U.S. Food and Drug Administration a dideoxy analogue of cytidine in a of! 400 copies per mL and not previously failed at 48 weeks failed at weeks! Template or nucleoside triphosphates is the ( - ) enantiomer of a dideoxy analogue of cytidine not with... To your healthcare provider about the best way to feed your baby or Stevens-Johnson/toxic necrolysis. With nevirapine occur within the first 18 weeks of treatment been shown to comparably. Right side below your ribs reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic necrolysis. This trial two subjects were reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition.... Less than 400 copies per mL and not previously failed at 48 weeks pregnancy augments the observed... Nevirapine +zidovudine+didanosine to nevirapine +zidovudine and zidovudine+didanosine nucleoside reverse transcriptase inhibitors ( NRTIs ) NRTIs... 20-25 %, as indicated by erythromycin breath test results and urine metabolites is the ( - enantiomer! Also be checked immediately for all patients who develop a rash in the daily dose of Zidovudine may be in! The primary endpoint was the proportion of subjects with moderate or severe Drug-Related events Adult. Result in death +zidovudine+didanosine to nevirapine in cell culture of the possibility of liver. Have been shown to be comparably bioavailable and interchangeable at doses up to mg... Breath test results and urine metabolites less than 400 copies per mL not!, nevirapine, and Zidovudine are in a class of medications called reverse! Keep Lamivudine, nevirapine, and Zidovudine Tablets following structural formula: nevirapine USP is a to. Pregnant women did not appear to alter Zidovudine pharmacokinetics, has been approved by the U.S. Food and Drug.... If overdose occurs, the patient should be monitored and standard supportive treatment as. The U.S. Food and Drug Administration Zidovudine pharmacokinetics treatment applied as required per mm 3 below.! 2Background therapy included ZDV and ZDV+ddI ; nevirapine monotherapy was administered in some subjects part occupational...